Literature DB >> 33184946

Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection.

Sha Lin1,2, Weilin Mao1,2, Qianda Zou1,2, Siming Lu1,2, Shufa Zheng1,2.   

Abstract

BACKGROUND: The emergence and rapid spread of the deadly novel coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a swiftly evolving public health crisis worldwide. SARS-CoV-2 infection is characterized by the development and progression of inflammatory responses. Hematological parameters, such as white blood cells (WBCs) and their subpopulations, red cell distribution width, platelet count, mean platelet volume, plateletcrit, and derived markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio, are established biomarkers of inflammatory responses. We aimed to investigate associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection.
METHODS: We retrospectively analyzed data from 68 patients with confirmed SARS-CoV-2 infection. Twenty-two patients had mild illness, and 46 had moderate or severe illness at the time of admission. Univariate and multivariate regression analyses were used to identify correlates of disease severity. The areas under receiver operating characteristic curves were calculated to estimate and compare the predictive values of different diagnostic markers.
RESULTS: Mean lymphocyte and monocyte counts were lower while WBC counts, neutrophil counts, NLR, and PLR were higher in patients with severe disease compared with those with mild disease (all P < .01). Univariate analysis revealed that older age, high WBC counts, high neutrophil counts, high NLR, high PLR, low monocyte counts, and low lymphocyte counts were independent correlates of severe illness. Multivariate analysis identified high NLR as the only independent correlate of severe illness. Receiver operating characteristic curve analysis showed that NLR had the highest area under curve of all hematological parameters.
CONCLUSION: Among hematological parameters, the NLR showed superior prediction of disease severity in patients with SARS-CoV-2 infection. Thus, the NLR could be a valuable parameter to complement conventional measures for identification of patients at high risk for severe disease.
© 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC.

Entities:  

Keywords:  SARS-CoV-2; disease severity; hematological parameters

Year:  2020        PMID: 33184946     DOI: 10.1002/jcla.23604

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  12 in total

1.  Soluble Angiotensin-Converting Enzyme 2 as a Prognostic Biomarker for Disease Progression in Patients Infected with SARS-CoV-2.

Authors:  Noelia Díaz-Troyano; Pablo Gabriel-Medina; Stephen Weber; Martin Klammer; Raquel Barquín-DelPino; Laura Castillo-Ribelles; Angels Esteban; Manuel Hernández-González; Roser Ferrer-Costa; Tomas Pumarola; Francisco Rodríguez-Frías
Journal:  Diagnostics (Basel)       Date:  2022-04-01

2.  Mean Platelet Volume as a Predictor of COVID-19 Severity: A Prospective Cohort Study in the Highlands of Peru.

Authors:  Jhosef Franck Quispe-Pari; Jose Armando Gonzales-Zamora; Judith Munive-Dionisio; Cristhian Castro-Contreras; Abelardo Villar-Astete; Cesar Kong-Paravicino; Pierina Vilcapoma-Balbin; Jorge Hurtado-Alegre
Journal:  Diseases       Date:  2022-04-15

3.  Does Neutrophil-to-lymphocyte Ratio at Admission Predict Severity and Mortality in COVID-19 Patients? A Systematic Review and Meta-analysis.

Authors:  Prattay Guha Sarkar; Pragya Pant; Jagmohan Kumar; Amit Kumar
Journal:  Indian J Crit Care Med       Date:  2022-03

4.  Value of the Neutrophil-Lymphocyte Ratio in Predicting COVID-19 Severity: A Meta-analysis.

Authors:  Ying Wang; Jingyi Zhao; Lan Yang; Junhui Hu; Yinhui Yao
Journal:  Dis Markers       Date:  2021-10-08       Impact factor: 3.434

5.  Identification of hematological and inflammatory parameters associated with disease severity in hospitalized patients of COVID-19.

Authors:  Ahuja Sana; Malviya Avneesh
Journal:  J Family Med Prim Care       Date:  2022-01-31

6.  Sex-Dependent Performance of the Neutrophil-to-Lymphocyte, Monocyte-to-Lymphocyte, Platelet-to-Lymphocyte and Mean Platelet Volume-to-Platelet Ratios in Discriminating COVID-19 Severity.

Authors:  Martha Fors; Santiago Ballaz; Hegira Ramírez; Francisco X Mora; Mary Pulgar-Sánchez; Kevin Chamorro; Esteban Fernández-Moreira
Journal:  Front Cardiovasc Med       Date:  2022-04-08

7.  Transient drop in the neutrophil count during COVID-19 regardless of clozapine treatment in patients with mental illness.

Authors:  Gabriel Vallecillo; Josep Marti-Bonany; Maria José Robles; Joan Ramón Fortuny; Fernando Lana; Victor Pérez
Journal:  Rev Psiquiatr Salud Ment (Engl Ed)       Date:  2022 Apr-Jun

Review 8.  The Role of Neutrophil-to-Lymphocyte Ratio in Risk Stratification and Prognostication of COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Ashwaghosha Parthasarathi; Sunag Padukudru; Sumalata Arunachal; Chetak Kadabasal Basavaraj; Mamidipudi Thirumala Krishna; Koustav Ganguly; Swapna Upadhyay; Mahesh Padukudru Anand
Journal:  Vaccines (Basel)       Date:  2022-08-01

9.  Role of red blood cell distribution width, as a prognostic indicator in COVID-19: A systematic review and meta-analysis.

Authors:  Soumya Sarkar; Sundara Kannan; Puneet Khanna; Akhil Kant Singh
Journal:  Rev Med Virol       Date:  2021-06-06       Impact factor: 11.043

10.  Early Routine Biomarkers of SARS-CoV-2 Morbidity and Mortality: Outcomes from an Emergency Section.

Authors:  Flavio Maria Ceci; Marco Fiore; Francesca Gavaruzzi; Antonio Angeloni; Marco Lucarelli; Carolina Scagnolari; Enea Bonci; Francesca Gabanella; Maria Grazia Di Certo; Christian Barbato; Carla Petrella; Antonio Greco; Marco De Vincentiis; Massimo Ralli; Claudio Passananti; Roberto Poscia; Antonio Minni; Mauro Ceccanti; Luigi Tarani; Giampiero Ferraguti
Journal:  Diagnostics (Basel)       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.